Kyle O’Neil
Consultant
Kyle M. O’Neil is a consultant at Back Bay Life Science Advisors, where he has completed over 45 projects across both therapeutics and medical devices. He has worked extensively across novel therapeutics (e.g., cell therapies, CRISPR, gene therapies, and RNA modalities), with a particular focus on rare diseases, neurology, and oncology.
Previously, Mr. O’Neil worked at GlaxoSmithKline, where he led a strategic assessment of clinical trial diversity for the US Clinical Operations team. Prior to GlaxoSmithKline, Mr. O’Neil also spent time at L’Oréal where he worked in Research and Innovation.
Mr. O’Neil holds both a B.S.E. and M.S.E. in Bioengineering from the University of Pennsylvania, where he was also a Fellow at the Penn Center for Innovation, a role in which he managed the technical, commercial, and legal aspects of technology disclosures for patentability and business decisions.
Select industry insights by Mr. O’Neil:
Companies and Themes to Watch at ASH 2021
Roaring 20s Redux: The Next Decade of Gene Therapy Innovation
Cell and Gene Therapy Investment Trends [Podcast]
Cell & Gene: The Next Decade In Gene Therapy Innovation, Six Critical Questions (And Answers)
Cell & Gene: An Analysis Of The Gene Therapy Viral Vector Landscape
Cell & Gene: The ABCs of Oncology: Looking Beyond Alpha-Beta Cells for Cell Therapies
Insights Magazine: Cell & Gene Therapy in Canada: Leading Companies and the Commercial Opportunity